BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Fourth Quarter and Fiscal Year 2017 on Monday, August 28, 2017, after the close of the stock market. PAREXEL will not host a conference call.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 52 countries around the world, and had approximately 18,900 employees at the end of the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
Contacts
PAREXEL International
Simon Harford, + 1-781-434-4118
Senior Vice President and Chief Financial Officer
IR@PAREXEL.com
or
Investors:
Ronald Aldridge, + 1-781-434-4753 or +1-781-434-8465
Senior Director, Investor Relations
Ron.Aldridge@PAREXEL.com
or
Media:
Mark Stephenson, + 1-781-434-4783
Vice President, Corporate Communication
Mark.Stephenson@PAREXEL.com
